Lacosamide - Isotope Labelled Standards
References
FAQ's
References
- Kohn, Harold, Anticonvulsant enantiomeric amino acid derivatives, WO9733861A1, Sep 18, 1997, Research Corporation Technologies, Inc., United States (https://patents.google.com/patent/WO1997033861A1/en)
- Kestelyn, C.; Lastelle, M.; Higuet, N.; Dell''Aiera, S.; Staelens, L.; Boulanger, P.; Boekens, H.; Smith, S., A simple HPLC-UV method for the determination of lacosamide in human plasma, Bioanalysis, Volume: 3, Issue: 22, Pages: 2515-2522, 2011 DOI: (10.4155/bio.11.261)
Frequently Asked Questions
2.What causes the formation of Lacosamide impurities?
Incomplete reaction conditions and reagents during the synthetic process are the source of Lacosamide impurities.
3.How does the Lacosamide drug degrade?
Lacosamide degrades under oxidative, alkaline, and acid hydrolytic conditions.
4.Which analytical technique identify Lacosamide degradation products?
Liquid chromatography hybrid ion trap/time-of-flight mass spectrometry (LC-IT/TOF-MS) and Liquid chromatography hybrid triple quadrupole-linear ion trap mass spectrometry (LC–QqLIT-MS) identify Lacosamide degradation products.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.